Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury
2022; Arán Ediciones; Linguagem: Inglês
10.17235/reed.2022.8618/2022
ISSN2340-4167
AutoresFlor M Fernández-Gordón Sánchez, Elena Gómez Domínguez, Diana Paredes-Ruíz, Yolanda Rodrı́guez Gil, Ana Martín Algíbez, Inmaculada Fernández, P Martínez Montiel,
Tópico(s)Inflammatory Bowel Disease
ResumoPembrolizumab, a programmed cell death receptor (PD-1) inhibitor, have improved the prognosis in several types of cancer. Despite the important clinical benefits, checkpoint inhibition have been associated with inflammatory and immune-related side effects (irAE).
Referência(s)